Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has announced that Shionogi & Co will expand its current research license to cover the use of the company's HuCAL Platinum technology in drug discovery. In April 2009, MorphoSys and Shionogi entered into an agreement under which, for pre-agreed terms, Shionogi could gain access to HuCAL Platinum, an antibody library, for a six-month beta test period.
Subscribe to our email newsletter
During the test period, Shionogi was able to compare HuCAL Platinum with its predecessor HuCAL Gold, and found the new library to be considerably better.
As per the agreement, Shionogi will now have the right to use HuCAL Platinum for research purposes at one of its sites. As a result of the expansion, MorphoSys will receive increased annual user fees from Shionogi.
Marlies Sproll, chief scientific officer of MorphoSys, said: “Shionogi has been able to test-drive the latest version of our antibody library HuCAL Platinum extensively. Thus, their decision to upgrade speaks clearly to the quality and the success of our internal technology development work in recent years.”
Earlier in September 2005, MorphoSys and Shionogi signed a three-year license agreement on the use of the former’s HuCAL technology. Under the terms of the agreement, MorphoSys granted Shionogi access to its HuCAL Gold antibody library for research applications in Shionogi’s drug discovery programs. The research alliance was extended for three additional years in September 2008.